Literature DB >> 3942999

Long-term survival and prognostic factors in breast cancer patients with localized (no skin, muscle, or chest wall attachment) disease with and without positive lymph nodes.

C M Sutherland, F J Mather.   

Abstract

Uncertainty exists regarding the magnitude of excess mortality from localized breast cancer at long follow-up times (greater than 15 years) since diagnosis and regarding the effects of race and age as prognostic factors at all follow-up times. Long-term survival was determined in 1141 patients (311 white, 830 black) diagnosed as having localized breast cancer with and without positive axillary lymph nodes, but without any signs of complete or incomplete skin, muscle, or chest wall attachment. Survival curves were estimated by means of actuarial methods; prognostic factors were evaluated with the Cox's regression analysis. Survival from all causes was 62%, 43%, 33%, 25%, and 18% at 5, 10, 15, 20, and 30 years, respectively. Breast cancer-specific survival was 76%, 65%, 63%, 61%, and 59% at 5, 10, 15, 20, and 30 years, respectively. Breast cancer-specific hazard rates exceeded those expected in the general population by 119 times, 53 times, 12 times, and 6 times at 0 to 5, 5 to 10, 10 to 20, and 20 to 25 years, respectively. Of the 395 patients enrolled after 1968 who had modified radical or radical surgery, 338 had known number of positive nodes and size of tumor. Breast cancer-specific survival was significantly increased with: a decreasing number of positive lymph nodes, 0, 1 to 3, and 4 or more (P = 0.000); later year of diagnosis (1974 or before versus 1975 or later) (P = 0.000); and possibly, tumor size of 7.0 cm or less (P = 0.09). When these variables were controlled, no significant association of age at diagnosis or race with breast cancer-specific survival was found. These data suggest that the number of nodes, year of diagnosis and, possibly, tumor size are important prognostic factors for survival, but race and age are not. Also, excess mortality may exist at late intervals; however, it is small in relation to other causes.

Entities:  

Mesh:

Year:  1986        PMID: 3942999     DOI: 10.1002/1097-0142(19860201)57:3<622::aid-cncr2820570338>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Charity Hospital experience with long-term survival and prognostic factors in patients with breast cancer with localized or regional disease.

Authors:  C M Sutherland; F J Mather
Journal:  Ann Surg       Date:  1988-05       Impact factor: 12.969

2.  Racial Differences in Hospital Stays among Patients Undergoing Craniotomy for Tumour Resection at a Single Academic Hospital.

Authors:  John P Sheppard; Carlito Lagman; Prasanth Romiyo; Thien Nguyen; Daniel Azzam; Yasmine Alkhalid; Courtney Duong; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2019-10

3.  Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma.

Authors:  Yihui Tang; Jianxian Lin; Junpeng Lin; Jiabin Wang; Jun Lu; Qiyue Chen; Longlong Cao; Mi Lin; Ruhong Tu; Changming Huang; Ping Li; Chaohui Zheng; Jianwei Xie
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 5.087

4.  Skin invasion and prognosis in node negative breast cancer: a retrospective study.

Authors:  Keiichiro Tada; Hidetomo Morizono; Kotaro Iijima; Yumi Miyagi; Seiichiro Nishimura; Masujiro Makita; Rie Horii; Futoshi Akiyama; Takuji Iwase
Journal:  World J Surg Oncol       Date:  2008-01-30       Impact factor: 2.754

5.  Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer.

Authors:  O P Kallioniemi; H Oksa; R K Aaran; T Hietanen; M Lehtinen; T Koivula
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

6.  Tumour DNA ploidy as an independent prognostic factor in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; T Koivula
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.